novel AIDS DNA vaccine - HKU Li Ka Shing Faculty of Medicine
... Cytokines Cytotoxicity MHC II CD40 ...
... Cytokines Cytotoxicity MHC II CD40 ...
1 Summer Research Opportunities
... mechanisms responsible for inflammatory cell recruitment into the injured cornea and this may define new therapeutic targets for regulating inflammation while still preserving the benefits it brings to wound healing. ...
... mechanisms responsible for inflammatory cell recruitment into the injured cornea and this may define new therapeutic targets for regulating inflammation while still preserving the benefits it brings to wound healing. ...
LECTURE 8 Immunopathologic processes Theme 11. Immune
... accumulation of coarsely dispersed proteins, fibrin, immune complexes, cellular elements – erythrocytes, neutrophils, eosinophils. In case repeated antigen coming these activated cells separate vasoactive substances – histamine and various ferments, which starts bloodstream exudative reaction. In ...
... accumulation of coarsely dispersed proteins, fibrin, immune complexes, cellular elements – erythrocytes, neutrophils, eosinophils. In case repeated antigen coming these activated cells separate vasoactive substances – histamine and various ferments, which starts bloodstream exudative reaction. In ...
Diagnosis of primary immunodeficiencies
... Available to most doctors, the CBC is a crucial test because it reveals any severe defects in the blood that could be caused by a PID. For example, patients with SCID, one of the most serious forms of PID, typically have very low levels of T cells. SCID is a medical emergency as infants with the con ...
... Available to most doctors, the CBC is a crucial test because it reveals any severe defects in the blood that could be caused by a PID. For example, patients with SCID, one of the most serious forms of PID, typically have very low levels of T cells. SCID is a medical emergency as infants with the con ...
Autoimmunity - Lehigh University
... - a synthetic peptide is used to bind in place of the regular peptide on the MHC - induces a state of clonal anergy in the autoimmune T-cells ...
... - a synthetic peptide is used to bind in place of the regular peptide on the MHC - induces a state of clonal anergy in the autoimmune T-cells ...
T-Cell Response to B-Cells and Epstein-Barr
... These results support our hypothesis (14, 21) that the lytic function of the T-lymphocytes in the acute phase of IM is not determined by the recognition of EBV-related antigen on the target but is rather a consequence of their activation. Cytotoxic function of lymphocyte populations exerted against ...
... These results support our hypothesis (14, 21) that the lytic function of the T-lymphocytes in the acute phase of IM is not determined by the recognition of EBV-related antigen on the target but is rather a consequence of their activation. Cytotoxic function of lymphocyte populations exerted against ...
LYMPHOID NEOPLASMS
... clinically and histologically distinct from the NHLs. In addition, it is treated in a unique fashion, making the differentiation of Hodgkin lymphoma and NHL clinically important. The other important category of lymphoid neoplasms encompasses the plasma-cell neoplasms, tumors composed of terminally d ...
... clinically and histologically distinct from the NHLs. In addition, it is treated in a unique fashion, making the differentiation of Hodgkin lymphoma and NHL clinically important. The other important category of lymphoid neoplasms encompasses the plasma-cell neoplasms, tumors composed of terminally d ...
Series introduction: innate host defense of the respiratory
... pathogens are cleared from the lung without inflammation or disturbance of the local function or structure. In case this first line host-defense system fails to clear the microorganism, secondary layers of the system are activated that are accompanied by an inflammatory reaction. The devastating eff ...
... pathogens are cleared from the lung without inflammation or disturbance of the local function or structure. In case this first line host-defense system fails to clear the microorganism, secondary layers of the system are activated that are accompanied by an inflammatory reaction. The devastating eff ...
Targeting TLR-4 with a novel pharmaceutical grade plant derived
... Immunomax activation of dendritic cells in vitro Sorted S-DC or BM-DC (2 × 104 cells in 200 μl of the complete culture medium) were incubated for 20 hrs at 37°C and 5% CO2 in 96-well culture plate in the absence or presence of Immunomax® (10 μg/ml). After incubation, cells were stained with CD8 ...
... Immunomax activation of dendritic cells in vitro Sorted S-DC or BM-DC (2 × 104 cells in 200 μl of the complete culture medium) were incubated for 20 hrs at 37°C and 5% CO2 in 96-well culture plate in the absence or presence of Immunomax® (10 μg/ml). After incubation, cells were stained with CD8 ...
Protocol S1.
... 13. Any clinically significant history of known or suspected anaphylaxis or hypersensitivity reaction based on the judgement of the investigator 14. Employee at the investigational site, relative or spouse of the investigator 15. Any other criteria which, in the investigator’s opinion, would comprom ...
... 13. Any clinically significant history of known or suspected anaphylaxis or hypersensitivity reaction based on the judgement of the investigator 14. Employee at the investigational site, relative or spouse of the investigator 15. Any other criteria which, in the investigator’s opinion, would comprom ...
B Cells in Health and Disease
... cell. The internalized antigen is broken down into peptides in lysozomes, some of which bind to major histocompatibility complex class II molecules. The peptide/major histocompatibility complex class II molecules are then transported to the surface of the B cell for presentation to CD4+ helper T cel ...
... cell. The internalized antigen is broken down into peptides in lysozomes, some of which bind to major histocompatibility complex class II molecules. The peptide/major histocompatibility complex class II molecules are then transported to the surface of the B cell for presentation to CD4+ helper T cel ...
Hemophagocytic Lymphohistiocytosis (HLH)
... Family history often negative Triggered by infections Presence of perforin gene mutation leads to deficiency in triggering of apoptosis Only 20-40% of familial HLH have perforin mutation H-Munc 13-4 (17q25) discovered 2003 assoc FHLH ...
... Family history often negative Triggered by infections Presence of perforin gene mutation leads to deficiency in triggering of apoptosis Only 20-40% of familial HLH have perforin mutation H-Munc 13-4 (17q25) discovered 2003 assoc FHLH ...
PERSPECTIVES
... preparations — either allogeneic or xenogeneic. This model had been validated previously by Simonsen29, and the resulting growth of lymphocyte colonies was regarded widely as being consistent with Burnet’s theory of clonal selection. To their surprise, Lafferty and Jones28 found that “as the genetic ...
... preparations — either allogeneic or xenogeneic. This model had been validated previously by Simonsen29, and the resulting growth of lymphocyte colonies was regarded widely as being consistent with Burnet’s theory of clonal selection. To their surprise, Lafferty and Jones28 found that “as the genetic ...
snews
... others that live peacefully in your intestines, helping your body run smoothly. (The latter type are called "commensal" bacteria.) This may be a problem for fighting the flu. Researchers from Yale University say that when mice which were already on antibiotics were infected with the flu virus, they ...
... others that live peacefully in your intestines, helping your body run smoothly. (The latter type are called "commensal" bacteria.) This may be a problem for fighting the flu. Researchers from Yale University say that when mice which were already on antibiotics were infected with the flu virus, they ...
(SLE).
... Interferon-alpha in SLE • Family of type I IFNs: IFN-α, IFN-β - induced by DNA and RNA virus infection (through intracellular nucleic acid receptors or after engagement of TLR: TLR3 for double-stranded RNA, TLR7 or -8 for single-stranded RNA, or TLR9 for demethylated CpG-richDNA) - mainly by plasma ...
... Interferon-alpha in SLE • Family of type I IFNs: IFN-α, IFN-β - induced by DNA and RNA virus infection (through intracellular nucleic acid receptors or after engagement of TLR: TLR3 for double-stranded RNA, TLR7 or -8 for single-stranded RNA, or TLR9 for demethylated CpG-richDNA) - mainly by plasma ...
Full Text - PDF - Global Advanced Research Journals
... The inoculation of trypanosomes into their mammalian hosts triggers a series of events involving, at first, innate immunity and, secondly, specific immunity. The latter requires an efficient presentation of parasitic antigens, activation of T and B cells implying specific antigen receptor recognitio ...
... The inoculation of trypanosomes into their mammalian hosts triggers a series of events involving, at first, innate immunity and, secondly, specific immunity. The latter requires an efficient presentation of parasitic antigens, activation of T and B cells implying specific antigen receptor recognitio ...
Clinical research - Wales Cancer Partnership
... 1. Dr Sahar Iqbal – Wales Cancer Research Centre Clinical Research ...
... 1. Dr Sahar Iqbal – Wales Cancer Research Centre Clinical Research ...
Cancer immunotherapy
Cancer immunotherapy (immuno-oncology) is the use of the immune system to treat cancer. Immunotherapies fall into three main groups: cellular, antibody and cytokine. They exploit the fact that cancer cells often have subtly different molecules on their surface that can be detected by the immune system. These molecules, known as cancer antigens, are most commonly proteins, but also include molecules such as carbohydrates. Immunotherapy is used to provoke the immune system into attacking the tumor cells by using these antigens as targets.Antibody therapies are the most successful immunotherapy, treating a wide range of cancers. Antibodies are proteins produced by the immune system that bind to a target antigen on the cell surface. In normal physiology the immune system uses them to fight pathogens. Each antibody is specific to one or a few proteins. Those that bind to cancer antigens are used to treat cancer. Cell surface receptors are common targets for antibody therapies and include the CD20, CD274, and CD279. Once bound to a cancer antigen, antibodies can induce antibody-dependent cell-mediated cytotoxicity, activate the complement system, or prevent a receptor from interacting with its ligand, all of which can lead to cell death. Multiple antibodies are approved to treat cancer, including Alemtuzumab, Ipilimumab, Nivolumab, Ofatumumab, and Rituximab.Cellular therapies, also known as cancer vaccines, usually involve the removal of immune cells from the blood or from a tumor. Immune cells specific for the tumor are activated, cultured and returned to the patient where the immune cells attack the cancer. Cell types that can be used in this way are natural killer cells, lymphokine-activated killer cells, cytotoxic T cells and dendritic cells. The only cell-based therapy approved in the US is Dendreon's Provenge, for the treatment of prostate cancer.Interleukin-2 and interferon-α are examples of cytokines, proteins that regulate and coordinate the behaviour of the immune system. They have the ability to enhance anti-tumor activity and thus can be used as cancer treatments. Interferon-α is used in the treatment of hairy-cell leukaemia, AIDS-related Kaposi's sarcoma, follicular lymphoma, chronic myeloid leukaemia and malignant melanoma. Interleukin-2 is used in the treatment of malignant melanoma and renal cell carcinoma.